Quercetin-Arctigenin Co-Treatment Induces Mitochondrial Dysfunction and Apoptotic Cell Death Through Metabolic Stress in Malignant Mesothelioma Cells

Our plain-English summary of Quercetin-Arctigenin Co-Treatment Induces Mitochondrial Dysfunction and Apoptotic Cell Death Through Metabolic Stress in Malignant Mesothelioma Cells, by M.K. Cho, S.H. Lee, H.S. Nam, et al (Life, 2026).

The study

• Authors: M.K. Cho, S.H. Lee, H.S. Nam, Y.J. Lee
• Journal: Life
• Published: 2026;16(5)
• Read it: PubMed · Publisher · Free full text

Abstract

Malignant mesothelioma is an aggressive cancer with limited therapeutic options, highlighting the need for novel strategies targeting metabolic vulnerabilities. Natural polyphenols have gained attention due to their ability to modulate cellular metabolism and apoptosis-related signaling pathways. In this study, we investigated the combined anticancer effects of quercetin (QUE) and arctigenin (ATG) in human malignant mesothelioma cells. QUE and ATG reduced the viability of MSTO-211H cells in a time-dependent manner, while non-malignant mesothelial MeT-5A cells showed relatively limited sensitivity under the tested conditions. Compared with single treatment, the combination treatment further enhanced growth inhibition, with combination index analysis suggesting a potential synergistic interaction. Co-treatment significantly decreased intracellular ATP levels and increased caspase-3/7 activity, suggesting metabolic stress-associated apoptotic responses. Annexin V analysis confirmed increased apoptotic cell populations following combination treatment. Western blot analysis demonstrated reduced expression of anti-apoptotic proteins Mcl-1 and Bcl-xL, along with increased cleavage of caspase-3 and PARP, consistent with involvement of intrinsic apoptosis-associated signaling pathways. In addition, increased phosphorylation of AMPK and altered expression of mitochondrial oxidative phosphorylation (OXPHOS) complex proteins were associated with potential alterations in mitochondrial respiratory protein expression. Collectively, these findings suggest that QUE and ATG co-treatment is associated with increased apoptotic cell death in malignant mesothelioma cells in association with metabolic stress-related mitochondrial functional alterations.

In plain English

This was a laboratory study of cells grown in dishes. It did not study people or asbestos exposure. The authors tested two plant compounds, quercetin (40 micromolar) and arctigenin (50 micromolar), alone and together. They used one human malignant mesothelioma cell line (MSTO-211H) and one non-malignant human mesothelial cell line (MeT-5A). In the mesothelioma cells, the combination lowered metabolic activity to approximately 70–75%, 58–62% and 40–48% of untreated cells at 24, 48 and 72 hours. That was more than either compound alone. The non-malignant cells stayed above approximately 95%. A combination index below 1 at 48 and 72 hours suggested a potential synergistic interaction. After 48 hours of combined treatment, approximately 35–45% of mesothelioma cells were apoptotic (undergoing programmed cell death). The figures were approximately 15–18% with quercetin alone and 14–17% with arctigenin alone. The combination also lowered cell energy (ATP) and several mitochondrial proteins. The authors concluded that the combination is associated with metabolic stress-related changes linked to apoptosis signaling in mesothelioma cells. They noted that the findings come mainly from in vitro models and need testing in more complex biological systems.

We wrote this plain-English summary from the full article with the help of AI, and a second AI model checked each sentence against the article. It is not the authors' wording; the abstract and the article are their own account.

What the study did and found

• Design: Laboratory (in vitro) cell culture experiment
• Who was studied: Two commercially obtained human cell lines: MSTO-211H malignant mesothelioma cells and MeT-5A non-malignant mesothelial cells. No human subjects or animals were studied.
• Exposure: Quercetin (QUE) at 40 µM and arctigenin (ATG) at 50 µM, alone or combined, for 24, 48 and 72 hours (48 hours for most mechanistic tests). Asbestos exposure was not studied.
• Main results:
  • In MSTO-211H mesothelioma cells, combined treatment reduced relative metabolic activity (MTT assay) to approximately 70–75%, 58–62% and 40–48% of untreated control at 24, 48 and 72 h. With QUE alone the values were approximately 80%, 65–70% and 55–60%. With ATG alone they were approximately 88–92%, 75–80% and 70%.
  • In non-malignant MeT-5A cells, relative metabolic activity stayed above approximately 95% under all treatments and time points.
  • In MSTO-211H cells, combination index values were below 1 at 48 and 72 h. The authors interpreted this as suggesting a potential synergistic interaction. In MeT-5A cells, values stayed close to or above one.
  • In MSTO-211H cells, the combination reduced intracellular ATP more than either compound alone. The text gives no numbers for this result.
  • In MSTO-211H cells after 48 h, caspase-3/7 activity rose approximately 1.8–2.2-fold versus control with the combination. The rise was approximately 1.3–1.5-fold with QUE alone and 1.2–1.4-fold with ATG alone.
  • In MSTO-211H cells (Annexin V staining, 48 h), total apoptotic cells were approximately 35–45% with the combination. They were approximately 15–18% with QUE alone, 14–17% with ATG alone, and below approximately 8–10% in untreated controls. In MeT-5A cells, apoptotic cells stayed below approximately 10–12% under all treatments.
  • In MSTO-211H cells, the combination lowered anti-apoptotic proteins relative to control: Mcl-1 to 0.52-fold, Bcl-xL to 0.38-fold and Bcl-2 to 0.60-fold. These proteins stayed at 0.97–1.00-fold in MeT-5A cells.
  • In MSTO-211H cells, combined treatment raised cleaved caspase-3 to 1.57-fold, cleaved PARP to 1.43-fold and AMPK phosphorylation to 1.83-fold relative to control.
  • In MSTO-211H cells, combined treatment reduced several mitochondrial OXPHOS proteins: ATP5A to 0.63-fold, UQCRC2 to 0.31-fold, SDHB to 0.18-fold and COX II to 0.20-fold. NDUFB8 stayed relatively stable. In MeT-5A cells, OXPHOS proteins ranged from 0.97- to 1.02-fold of control.
• The authors' conclusion: The authors concluded that combined exposure to quercetin and arctigenin is associated with metabolic stress-related changes linked to apoptosis signaling in mesothelioma cells. They said this supports further investigation of combination strategies targeting metabolic mechanisms in mesothelioma.
• Limitations the authors state:
  • The findings come mainly from in vitro models. Further studies are needed to see whether similar effects occur in more complex biological systems.
  • The authors said mitochondrial function itself (respiration rate, mitochondrial membrane potential, reactive oxygen species production) needs further investigation.
  • The authors said testing in 3D culture systems or in living animals (in vivo) may clarify how relevant the findings are beyond the dish.

Topics

Medical terms in this study, explained in our Lexicon: Mesothelioma, Apoptosis, MeT-5A Cells.

Related studies

• Pifithrin-μ induces necroptosis through oxidative mitochondrial damage but accompanies epithelial-mesenchymal transition-like phenomenon in malignant mesothelioma cells under lactic acidosis — Y.J. Lee, K.S. Park, et al. (2019)
• Auranofin induces mesothelioma cell death through oxidative stress and GSH depletion — B.R. You, W.H. Park (2016)
• Apigenin causes necroptosis by inducing ROS accumulation, mitochondrial dysfunction, and ATP depletion in malignant mesothelioma cells — Y.J. Lee, K.S. Park, et al. (2020)
• Cisplatin and resveratrol induce apoptosis and autophagy following oxidative stress in malignant mesothelioma cells — Y.J. Lee, G.J. Lee, et al. (2016)
• Asbestos induces mitochondrial DNA damage and dysfunction linked to the development of apoptosis — A. Shukla, M. Jung, et al. (2003)
• Licochalcone A induces apoptosis in malignant pleural mesothelioma through downregulation of Sp1 and subsequent activation of mitochondria-related apoptotic pathway — K.H. Kim, G. Yoon, et al. (2015)

Browse more research in Life, or return to medical research.